MAE and RMSE stratified by mobility impairment and health-utility severity.
| Mobility impairment | MAE (SD) | RMSE |
|---|---|---|
| PDDS* | ||
| No mobility impairment (n=1299, 40.4%) | 0.141 (0.128) | 0.190 |
| Moderate mobility impairment (n=1835, 57.1%) | 0.087 (0.061) | 0.107 |
| Severe mobility impairment (n=80, 2.5%) | 0.121 (0.049) | 0.130 |
| NARCOMS mobility performance scale*† | ||
| Normal (n=613, 18.9%) | 0.212 (0.138) | 0.252 |
| Minimal gait disability (n=549, 17%) | 0.077 (0.077) | 0.109 |
| Mild gait disability (n=509, 15.7%) | 0.071 (0.056) | 0.089 |
| Occasional use of cane (n=570, 17.6%) | 0.077 (0.056) | 0.095 |
| Frequent use of cane (n=493, 15.2%) | 0.094 (0.065) | 0.114 |
| Severe gait disability (n=454, 14%) | 0.109 (0.064) | 0.127 |
| Total gait disability (n=47, 1.5%) | 0.131 (0.053) | 0.142 |
| EQ-5D health state | ||
| <0.50 (n=438, 12.5%) | 0.297 (0.094) | 0.312 |
| 0.50 to <0.75 (n=867, 24.7%) | 0.063 (0.054) | 0.083 |
| ≥0.75 (n=2200, 62.8%) | 0.089 (0.060) | 0.107 |
*Sample does not add up to 3505 due to missing disease-severity data.
†Responses are to the item, ‘In the past 4 weeks, compare your current condition with your mobility before you developed MS.’
EQ-5D, EuroQol 5-dimension; MAE, mean absolute error; NARCOMS, North American Research Committee on Multiple Sclerosis; PDDSs, patient-determined disease steps; RMSE, root mean square error.